Program
Wednesday September 26th
Arrival in the afternoon.
Registration opened at 17:30
| 18:30 | Opening of the workshop |
| Organizing committee | |
|
18:35 - 18:45 |
Presentation of the "Tumour targeting & Radiotherapies network" of the Cancéropôle Grand Ouest |
| Dimitris Visvikis, LaTIM, National Institute of Health & Clinical Sciences, Brest, France. | |
|
18:45 - 19:05 |
Sponsors communications |
|
“When chelates make the différence in targeted PET imaging and radiotherapy with radiometals” - EASYCHELATORS |
|
|
19:05 - 20:00 |
"Nanogalenic and therapeutic innovation" |
| Invited speaker: Patrick Couvreur, Institut Galien, UMR CNRS 8612, Paris Saclay University, Chatenay Malabry, France. | |
| 20:15 | Dinner |
Thursday September 27th
Session 1: How to identify an adequate target?
Session 1a: How to identify a tumour target?
|
9:00 - 9:30
|
"Hit-finding strategies: from high-throughput screening to DNA-encoded libraries" |
| Invited speaker: Alexander Satz, Roche, Switzerland. | |
|
9:30 - 10:30
|
“Contribution of molecular modelling to the development of virus-like particles for breast cancer theranostics“ |
| Rita Melo, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal. | |
| “Synthesis and biological validation of macrocyclic CXCR4 and ACKR3 binding agents for PET imaging and therapeutic applications in cancer” | |
| Isaline Renard, Department of Chemistry and Positron Emission Tomography Research Centre, University of Hull, United Kingdom. | |
| "Radiobiological characterization of 64CuCL2 for prostate cancer theranostics" | |
| Joana F. Guerreiro, C2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal. | |
| 10:30 - 11:00 | Poster session & Coffee break |
|
11:00 - 12:00
|
“A versatile nanoemulsion for functionalization with different specific ligands for targeted drug delivery” |
| Sainza Lores, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. | |
| “New approaches for the utilization of Affibody molecules in cancer therapy: reviving an old dream” | |
| Mohamed Altai, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. | |
| “Combining 2D angiogenesis and 3D Osteosarcoma microtissues to improve vascularization” | |
| Hassan Chaddad, INSERM, UMR 1260, Regenerative Nanomedicine, FMTS & Université de Strasbourg, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg, France. | |
| 12:00 - 12:10 | Sponsor communication - MILabs |
| 12:15 | Lunch |
| Session 1b: How to choose a target for antitumour immune response? | |
|
14:00 - 14:30
|
"MELOE-1 antigen: a model of immunogenic target for melanoma immunotherapy" |
|
Invited speaker: Nathalie Labarrière, CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France.
|
|
|
14:30 - 15:30
|
“Relationship between the Location of Intraprostatic Hybrid Tracer Deposition and Lymph Node Visualization“ |
|
Clarize. M. de Korne, Interventional Molecular Imaging Laboratory, Department of Radiology, University Medical Center, Leiden, The Netherlands. |
|
| “Inactivation of PD-1 gene in melanoma-specific CD8+ T lymphocytes” | |
| Lucine Marotte, CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France. | |
| “Alpha-Radioimmunotherapy targeting PD-L1 in melanoma“ | |
|
Marisa Fernandes - Capitao, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France, France. |
|
| 15:30 - 16:00 | Coffee break |
| 16:00 - 17:00 | “A novel strategy to identify melanoma antigens from long non coding RNA“ |
| Emilie Dupré, CRCINA, INSERM, Université d’Angers, Université de Nantes, & Labex IGO, Nantes, France. | |
| “Impact of RIT-alpha on the tumor microenvironnement“ | |
| Justine Perrin, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France. | |
| “The inflammasome of tumor cells in colorectal cancer: a potential target to strengthen the Th1/Tc1 response of tumor infiltrating T lymphocytes (TILs)” | |
|
Linda Bilonda, Institut Roche, Boulogne-Billancourt, France & CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes,
France. |
|
| 20:00 | Dinner |
Friday September 28th
Session 2: What are strategies to reach a tumour target?
|
9:00 - 9:30 |
“Peptides like drones: identify and reach the target" |
|
Invited speaker: Stefania Galdiero, Department of Pharmacy, University of Naples “Federico II”, Italy.
|
|
|
9:30 - 10:30
|
“Self-assembly of prodrugs formed by cell-penetrating peptide and ferrocifen for lung cancer treatment” |
|
Léna Guyon, MINT, Inserm U1066/CNRS 6021, Angers, France. |
|
|
“Down-regulation efficiency and intracellular trafficking of siRNA nanovectors for triple negative breast cancer treatment“ |
|
|
Sanaa Ben Djemaa, EA6295 Nanomédicaments et Nanosondes, University of Tours, France. |
|
|
“Targeting melanoma tumor cells with pH-responsive lipid nanocapsules: in vitro and in vivo studies” |
|
|
Vincent Pautu, MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France. |
|
| 10:30 - 11:00 | Poster session & Coffee break |
|
11:00 - 12:00
|
“Magnetic NPs for breast cancer targeting: Controlling single-chain variable fragment antibody orientation during bioconjugation” |
| Colin Moore, EA6295 NMNS, Université de Tours, France. | |
| “Paclitaxel/SPIO-loaded PLGA-based nanoparticles for the imaging and therapeutic targeting of glioblastoma” | |
| Lakshmi Pallavi Ganipineni, Université catholique de Louvain, Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Brussels, Belgium. | |
| “Targeting the SDF-1α/CXCR4 Signalling Axis for Trapping of Glioblastoma Cells” | |
| Muhammad Haji Mansor, CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France. | |
| 12:15 | Lunch |
|
14:00 - 14:30
|
"Small is beautiful: Single domain antibodies for cancer diagnostic and therapy" |
|
Invited speaker: Patrick Chames, CRCM, Cancer Research Center of Marseille, UMR INSERM 1068 CNRS 7258, Marseille, France. |
|
| 14:30 - 15:30 | “Inhibition of heparanase-mediated tumor progression by natural sulfated polysaccharide derivatives” |
| Rémi Cousin, UMR CNRS 7266 LIENSs, BCBS group (Biotechnologies and Chemistry applied to Bioressources for health), University of La Rochelle, France. | |
| “Hypoxia imaging: interest of Image-Guided Radiotherapy for the treatment of brain metastases from lung cancer, a preclinical study” | |
| Aurélien Corroyer-Dulmont, Normandie Univ, UNICAEN, CEA, CNRS, ISTCT laboratory/CERVOxy group, Caen, France. | |
| “Theranostic agents for TEM1 targeting: towards clickable radioimmunoconjugates“ | |
| Alice D’Onofrio, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal. | |
| 15:30 - 16:00 | Coffee break |
|
16:00 - 17:00
|
“Preclinical CDK4/6 inhibition for Squamous Cell Carcinoma of the Head and Neck (SCCHN)“ |
| Gabrielle van Caloen, Institut de Recherche Clinique et Expérimentale (MIRO), Université Catholique de Louvain, Brussels, Belgium. | |
| “CD38: a promising marker for immuno-PET imaging of MM” | |
| Benjamin Chalopin, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France. | |
| “Optimization of ADAPT6, a new scaffold protein-based probe for radionuclide molecular imaging of cancer“ | |
| Javad Garousi, Uppsala University, Uppsala, Sweden. | |
| 17:00 - 23:00 | Social event |
Saturday September 29th
Session 3: Input of imaging in the follow-up of a tumour targeting & Advances of multimodality for imaging and therapy
|
9:00 - 9:30
|
“Integrating PET imaging with Nanomedicine for gammadelta T-cell Immunotherapy” |
| Invited speaker: Rafael T.M. de Rosales, Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London, United-Kingdom. | |
| 9:30 - 10:30 | “Intracranial gliobalstoma follow-up study by multimodal imaging methods” |
| Nikolett Hegedűs, Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary. | |
| “Stable and inert lanthanide(III) complexes with pyclen-based ligand bearing picolinate arms for liver cancer diagnostic and therapy“ | |
| Gwladys Nizou, Université de Bretagne Occidentale, UMR-CNRS 6521, IBSAM, UFR des Sciences et Techniques, Brest, France. | |
| “Multimodal nanoemulsions for whole-body imaging in metastatic cancer” | |
| Sandra Díez-Villares, Nano-Oncology Unit, Translational Medical Oncology Group (ONCOMET). Health Research Institute of Santiago de Compostela (IDIS) and CIBERONC, Santiago de Compostela, Spain. | |
| 10:30 - 10:50 | Poster session & Coffee break |
|
10:50 - 11:50
|
“In vitro and in vivo trackable titanocene-based complexes using optical imaging or SPECT” |
|
Océane Florès, ICMUB, UMR 6302 CNRS, Université de Bourgogne, Dijon, France. |
|
|
“New Cu(II)-based monopicolinate cyclam derivatives for theranostic PET/PDT applications” |
|
|
Jonathan Mendy, Université de Bretagne Occidentale, UMR-CNRS 6521, IBSAM, UFR Sciences et Techniques, Brest, France. |
|
|
“Au@DTDTPA(Gd)-Cy5 nanoparticles for multimodality imaging in a Triple Negative Breast Cancer (TNBC) model“ |
|
| Océane Campion, Université de Reims Champagne-Ardenne, UFR Sciences Exactes et Naturelles & CNRS UMR 7369, MEDyC, Reims, France. | |
| 12:00 | Lunch |
| 13:10 | End of the workshop - Departure |
Other informations
Scientific sessions:
- Duration of selected talks is 20 minutes incl. questions.
Poster session:
- The format of poster is A0.
- Discussion around the posters will be possible during all coffee breaks. Posters should therefore be hanged for the entire duration of the workshop.
